Renal Pre-Competitive Consortium (RPC2): discovering therapeutic targets together.

Abstract

Despite significant effort, patients with kidney disease have not seen their outcomes improved significantly over the past two decades. This has motivated clinicians and researchers to consider alternative methods to identifying risk factors, disease progression markers, and effective therapies. Genome-scale data sets from patients with renal disease can be used to establish a platform to improve understanding of the molecular basis of disease; however, such studies require expertise and resources. To overcome these challenges, we formed an academic-industry consortium to share molecular target identification efforts and expertise across academia and the pharmaceutical industry. The Renal Pre-Competitive Consortium (RPC2) aims to accelerate novel drug development for kidney diseases through a systems biology approach. Here, we describe the rationale, philosophy, establishment, and initial results of this strategy.

• Authors: Mark Tomilo, Heather Ascani, Barbara Mirel, Maria Chiara Magnone, Carol Moreno Quinn, Anil Karihaloo, Kevin Duffin, Uptal D Patel, Matthias Kretzler
• Journal: Drug discovery today (Drug Discov Today) Vol. 23 Issue 10 Pg. 1695-1699 (10 2018) ISSN: 1878-5832 [Electronic] England
• PMID: 29778696 (Publication Type: Journal Article, Review)
• Copyright: Published by Elsevier Ltd.

Chemical References

• Biomarkers

Topics

• Animals
• Biomarkers (metabolism)
• Disease Progression
• Drug Design
• Drug Development (methods)
• Drug Industry (methods)
• Humans
• Kidney Diseases (drug therapy)
• Molecular Targeted Therapy
• Risk Factors
• Systems Biology (methods)